Madrigal Pharmaceuticals MDGL shares soared 10.9% on Wednesday. The uptrend was observed after the U.S. Patent and Trademark ...

Madrigal Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 73 to 87.

Madrigal Pharmaceuticals shares rose after the biopharmaceutical company received a U.S. patent for its Rezdiffra treatment. Shares were up 11% at $345.24 Wednesday. The stock has been up 12.8% this ...

The Notice of Allowance includes claims directed to Rezdiffra’s commercial weight-threshold dosing regimen as prescribed in the FDA-approved label. The U.S. patent scheduled to issue from this ...

The extended patent protection strengthens Madrigal’s market position by preventing generic competition for over two decades, potentially securing long-term revenue streams for the biopharmaceutical ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it ...

Earlier this year, Madrigal Pharmaceuticals (NASDAQ: MDGL) launched its first product, Rezdiffra. It wasn't just an important breakthrough for the mid-cap biotech; Rezdiffra became the first ...

Madrigal Pharmaceuticals is transitioning from clinical trials to market-ready solutions for non-alcoholic steatohepatitis and liver fibrosis. Read more here.

Madrigal plans to focus on approximately 315,000 diagnosed patients with NASH with moderate to advanced liver fibrosis under the care of the liver specialist physicians during the launch of Rezdiffra.

Madrigal Pharmaceuticals earned the first approval for a medicine in an area with a high unmet need. The biotech has more to do to dominate this market, considering it should become more crowded ...

About Madrigal Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a ...